Jonathan Silbiger, MD
Ophthalmology · Winter Haven, FLNPI 1174520423
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Alcon at 47.0% of the total. Reporting peaked in 2020 at $169 and has fallen 85.5% since, to $24 in 2025. That places this record below the midpoint for ophthalmology clinicians in FL, where the typical reported total is $1,824.
Across 13 payments — averaging $33.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$204
- Shire North American Group Inc$100
- Johnson & Johnson Surgical Vision, Inc.$71
- Sight Sciences, Inc.$36
- Glaukos Corporation$24
What the payments were for
- Food & beverage$434100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 6 | $204 |
| Shire North American Group Inc | 1 | $100 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $71 |
| Sight Sciences, Inc. | 2 | $36 |
| Glaukos Corporation | 1 | $24 |
How this compares
$434 in reported general payments places this provider in the 20th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 694 | $28,509 |
| RestasisCyclosporine | 25 | $22,689 |
| LumiganBimatoprost | 38 | $15,633 |
| XiidraLifitegrast | 18 | $13,629 |
| Latanoprost | 756 | $6,463 |
| BesivanceBesifloxacin Hcl | 25 | $5,668 |
| Alphagan PBrimonidine Tartrate | 14 | $4,657 |
| Ketorolac Tromethamine | 83 | $2,686 |
| Loteprednol Etabonate | 15 | $2,377 |
| Travoprost | 25 | $2,020 |
| Timolol Maleate | 119 | $1,974 |
| Ofloxacin | 129 | $1,842 |
| Brimonidine Tartrate | 125 | $1,591 |
| Difluprednate | 17 | $1,203 |
| MoxifloxacinMoxifloxacin Hcl | 42 | $1,194 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Winter Haven
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.